Woodlands-based biotechnology company, Opexa Therapeutics, Inc., has just revealed that a number of their important patents have been granted, giving the company a more competitive edge in the development of patient-specific immunotherapies.
The company authorizes and retains numerous patents for the treatment of autoimmune diseases such as Multiple Sclerosis (MS). Over the past year, Opexa has been granted 8 patents, including one issued by the European patent office not long ago. This patent counts as the 50th the company has received globally for its trademarked T-cell platform, and confirms Opexa as a front runner in the field of Precision Immunotherapy. The company currently has a an extensive patent portfolio, securing its technology in the USA, Europe and Asia.
Only recently approved and rendered valid in 18 countries in Europe is European patent no. 2335720. This patent encompasses the mass-production of patient-specific T-cell vaccines developed from immunogenic fragments of myelin proteins. It strengthens the application of Tcelna in treatment plans for MS. The company’s main pharmaceutical product, Tcelna, is a personalized T-cell immunotherapy presently going through Phase IIb in clinical development for the treatment of Secondary Progressive MS (SPMS). The United State Food and Drug Administration (FDA) has granted Tcelna a Fast Track Designation for SPMS.
Other patents that have been awarded to Opexa include European patent no. 1677821, which registers a T-cell vaccine enhanced with CD8+ T-cells, and Israeli patent no. 195115, given for personalized T-cell vaccines comprised of T-cells that are selective to the most immunogenic epitopes of encountered autoantigens. Last month, the company received another notice of allowance on the subject of U.S. patent application no. 12/306,894 for the employment of a personalized T-cell vaccine for rheumatoid arthritis.
The President and CEO of Opexa, Neil K. Warma, said that as a pioneer in the field of Precision Immunotherapy, the company deems it essential to further and protect their intellectual property internationally. Doing so would strengthen Opexa’s competitive edge and help increase shareholder value.